User:Mr. Ibrahem/Cisatracurium

Mr. Ibrahem/Cisatracurium
Clinical data
Trade names	Nimbex, others
Other names	Cisatracurium besilate, cisatracurium besylate, 51W89, cisatracurium besylate (USAN US)
AHFS/Drugs.com	Monograph
License data	US DailyMed: Cisatracurium_besylate;
Pregnancy; category	B;
Routes of; administration	Intravenous
Drug class	Neuromuscular blocking agent (non-depolarizing)
Legal status
Legal status	US: ℞-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	100% (IV)
Metabolism	80% Hofmann degradation / liver
Elimination half-life	20–29 minutes
Excretion	10-15% unchanged
Identifiers
	IUPAC name 5-[3-[(1R,2R)-1-[(3,4-Dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-yl]propanoyloxy]pentyl 3-[(1R,2R)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-yl]propanoate benzenesulfonate (1:2);
Chemical and physical data
Formula	C65H82N2O18S2
Molar mass	1243.49 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [O-]S(=O)(=O)c1ccccc1.[O-]S(=O)(=O)c1ccccc1.O=C(OCCCCCOC(=O)CC[N@@+]2([C@@H](c1c(cc(OC)c(OC)c1)CC2)Cc3ccc(OC)c(OC)c3)C)CC[N@+]5(C)[C@@H](c4cc(OC)c(OC)cc4CC5)Cc6ccc(OC)c(OC)c6;
	InChI InChI=1S/C53H72N2O12.2C6H6O3S/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6;27-10(8,9)6-4-2-1-3-5-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3;21-5H,(H,7,8,9)/q+2;;/p-2/t42-,43-,54-,55-;;/m1../s1 ; Key:XXZSQOVSEBAPGS-DONVQRBFSA-L ;
	(what is this?) (verify)

Cisatracurium, sold under the brand name Nimbex among others, is a medication used to help with endotracheal intubation and during surgery or mechanical ventilation.^[1]^[3] It is given by injection into a vein.^[2] It has intermediate onset and duration of action.^[2]^[1]

Common side effects include a slow heart rate.^[2] Other side effects may include allergic reactions, prolonged muscle weakness, and seizures.^[1] The dose does not need to be adjusted for liver or kidney problems.^[1] It is a neuromuscular blocking agent of the non-depolarizing type.^[1] It results in skeletal muscle relaxation.^[1]

Cisatracurium was approved for medical use in the United States in 1995.^[1] It is available as a generic medication.^[2] In the United Kingdom a 20 mg vial costs the NHS about £8 as of 2021.^[2] This amount in the United States is about 25 USD.^[4]

References

^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ "Cisatracurium Monograph for Professionals". Drugs.com. Archived from the original on 23 January 2021. Retrieved 5 January 2022.
^ ^a ^b ^c ^d ^e ^f BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1390. ISBN 978-0857114105.
^ "DailyMed - CISATRACURIUM BESYLATE injection". dailymed.nlm.nih.gov. Archived from the original on 28 March 2021. Retrieved 5 January 2022.
^ "Cisatracurium Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 5 January 2022.

[AHFS2022-1] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ "Cisatracurium Monograph for Professionals". Drugs.com. Archived from the original on 23 January 2021. Retrieved 5 January 2022.

[BNF81-2] ^ ^a ^b ^c ^d ^e ^f BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1390. ISBN 978-0857114105.

[PI2022-3] "DailyMed - CISATRACURIUM BESYLATE injection". dailymed.nlm.nih.gov. Archived from the original on 28 March 2021. Retrieved 5 January 2022.

[4] "Cisatracurium Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 5 January 2022.

[1]

[3]

[2]

[4]